Brokerages Set Savara Inc (NASDAQ:SVRA) Target Price at $8.83

Shares of Savara Inc (NASDAQ:SVRA) have been given a consensus rating of “Moderate Buy” by the six brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $8.83.

Several equities analysts recently issued reports on the company. Wells Fargo & Company assumed coverage on Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Savara in a research report on Thursday, December 19th.

Institutional Investors Weigh In On Savara

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cibc World Markets Corp acquired a new stake in Savara during the 4th quarter worth about $33,000. XTX Topco Ltd purchased a new stake in shares of Savara during the 4th quarter worth about $34,000. Ameriprise Financial Inc. purchased a new stake in shares of Savara during the 4th quarter worth about $37,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Savara during the 4th quarter worth about $41,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Savara during the 4th quarter worth about $48,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Price Performance

NASDAQ SVRA opened at $2.82 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock’s fifty day moving average price is $2.73 and its 200 day moving average price is $3.32. Savara has a 1 year low of $2.26 and a 1 year high of $5.34. The company has a market cap of $483.97 million, a price-to-earnings ratio of -6.56 and a beta of 0.60.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.